Prognostic Value of Cancer Stem Cell Marker CD133 Expression in Gastric Cancer: A Systematic Review

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Wen, Lei ^a   Chen, Xin Zu ^a   Yang, Kun ^a   Chen, Zhi Xin ^a   Zhang, Bo ^a   Chen, Jia Ping ^a   Zhou, Zong Guang ^a   Mo, Xian Ming ^a   Hu, Jian Kun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR VOLUME;

ANTIGENS, CD; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84875334076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059154     Document Type: Article

References (47)

1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, et al. (2009) Recent patterns in gastric cancer: A global overview. Int J Cancer 125: 666-673.
2. Ji JF (2003) Several surgical problems in the treatment of gastric cancer. Journal of Practical Oncology 18: 341-346. Chinese.
3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells: Perspectives on current status and future directions-AACR Workshop on Cancer Stem Cells. Cancer Res 66: 9339-9344.
4. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, et al. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958.
5. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
6. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514.
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
8. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
9. Horst D, Kriegl L, Engel J, Kirchner T, Jung A, (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289.
10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, et al. (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129.
11. Song W, Li H, Tao K, Li R, Song Z, et al. (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218.
12. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, et al. (2010) CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45: 896-902.
13. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. 2008. The Cochrane Collaboration website. Available: http://www.cochrane-handbook.org/. Accessed 15 January 2011.
14. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, et al. (2008) CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 98: 1389-1397.
15. Hibi K, Sakata M, Kitamura YH, Sakuraba K, Shirahata A, et al. (2010) Demethylation of the CD133 gene is frequently detected in early gastric carcinoma. Anticancer Res 30: 1201-1203.
16. Li YZ, Wang FH, Zhao P (2008) Expressions of CD133 and Ki-67 in gastric carcinoma and their clinicopathologic significances. World Chinese Journal of Digestology 16: 3167-3171. Chinese.
17. Zhang P, Wu JG, Yu JW, Ni XC, Wu HB, et al. (2011) Expression of CD133 protein in primary lesions of gastric cancer and its clinical significance. Chin J Bases Clin General Surg 18: 281-285. Chinese.
18. Zhang P, Wu JG, Wu HB, Wang ST, Yu JW, et al. (2010) Expression of CD133 mRNA in tissues of gastric cancer and its relationship with clincopathological features. Journal of Shanghai Jiaotong University (Medical Science) 30: 213-217. Chinese.
19. Boegl M, Prinz C, (2009) CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 100: 1365-1366.
20. Tang BF, Ma LY, Zhai YJ, Yu YW, Zhang MF, et al. (2008) Expression and clinical significance of cancer stem cellmarker CD133 in gastric cancer tissues. Chinese Clinical Oncology 13: 495-498. Chinese.
21. Yan JL, Qian H, Zhu W, Yan YM, Cao HL, et al. (2011) Detection and diagnostic significance of cancer stem cell marker CD133 for gastric cancer. Chin J Clin Lab Sci 29: 112-114. Chinese.
22. Xue YM, Sun PC, Wu G, Zhu YZ, Liao XN, et al. (2011) Expression of CD133 in tissue of gastric cancer and its clinical significance. Journal of Chinese Practical Diagnosis and Therapy 25: 355-357. Chinese.
23. Zhao P, Li Y, Lu Y, (2010) Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 10: 218-223.
24. Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, et al. (2010) Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 30: 2453-2457.
25. Yu JW, Zhang P, Wu JG, Wu SH, Li XQ, et al. (2010) Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocarcinoma. J Exp Clin Cancer Res 29: 141-150.
26. Wang T, Ong CW, Shi J, Srivastava S, Yan B, et al. (2011) Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer 105: 658-665.
27. Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, et al. (2008) Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol 14: 2715-2722.
28. Chen XZ, Zhang WK, Yang K, Wang LL, Liu J, et al. (2012) Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep 39: 9031-9039.
29. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, et al. (2011) Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 26: 173-180.
30. Siewert JR, Böttcher K, Stein HJ, Roder JD, (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228: 449-461.
31. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK, (1998) Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1: 125-133.
32. Weigmann A, Corbeil D, Hellwig A, Huttner WB, (1997) Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 94: 12425-12430.
33. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, et al. (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105: 13427-13432.
34. Horst D, Kriegl L, Engel J, Jung A, Kirchner T, (2009) CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45: 2034-2040.
35. Lu RQ, Wu JG, Zhou GC, Jiang HG, Ni XC, et al. (2011) Study on biological characteristics of CD133 positive population in gastric cancer cells by magnetic activated cell sorting in vitro. Clin J Bases Clin General Surg 18: 1265-1270. Chinese.
36. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
37. Yu GZ, Chen Y, Wang JJ, (2009) Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 135: 1331-1339.
38. Todaro M, Francipane MG, Medema JP, Stassi G, (2010) Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162.
39. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, et al. (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99: 100-109.
40. Rocco A, Liguori E, Pirozzi G, Tirino V, Compare D, et al. (2012) CD133 and CD44 Cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol 227: 2686-2693.
41. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2020.
42. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, et al. (2011) Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 26: 173-180.
43. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
44. Chen T, Yang K, Yu J, Meng W, Yuan D, et al. (2012) Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res 22: 248-258.
45. Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW, et al. (2012) CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis. BMC Gastroenterol 12: 95-101.
46. Fernandez JC, Vizoso FJ, Corte MD, Gava RR, Corte MG, et al. (2004) CD44s expression in resectable colorectal carcinomas and surrounding mucosa. Cancer Invest 22: 878-885.
47. Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, et al. (2007) A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. Journal of Surgical Oncology 95: 652-662.